NCT01371565 · OUTCOME

Number of Participants With Adverse Events

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome · Source last updated 2014-03-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 6 months

What was measured

Safety was assessed at all visits and adverse events were recorded.

Analysis population: Due to the small number of patients enrolled (N=4), no formal assessments were planned. All patients who received study drug were included in the safety review.

Groups in this outcome

Mifepristone

At doses from 300mg/day up to 1200mg/day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Mifepristone	4

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Mifepristone	4	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4

denoms

counts
group Id
OG000
value
4
units
Participants

description

Safety was assessed at all visits and adverse events were recorded.

groups

description
At doses from 300mg/day up to 1200mg/day
id
OG000
title
Mifepristone

param Type

NUMBER

population Description

Due to the small number of patients enrolled (N=4), no formal assessments were planned. All patients who received study drug were included in the safety review.

reporting Status

POSTED

time Frame

6 months

title

Number of Participants With Adverse Events

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice